342 related articles for article (PubMed ID: 26667803)
1. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
[TBL] [Abstract][Full Text] [Related]
2. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
3. Primary Aldosteronism: Present and Future.
Funder JW
Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
[TBL] [Abstract][Full Text] [Related]
4. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
6. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
8. Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys.
Cohen JB; Bancos I; Brown JM; Sarathy H; Turcu AF; Cohen DL
Annu Rev Med; 2023 Jan; 74():217-230. PubMed ID: 36375469
[TBL] [Abstract][Full Text] [Related]
9. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
10. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism.
Catena C; Colussi G; Di Fabio A; Valeri M; Marzano L; Uzzau A; Sechi LA
Horm Metab Res; 2010 Jun; 42(6):440-5. PubMed ID: 20119883
[TBL] [Abstract][Full Text] [Related]
12. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.
Amar L; Lorthioir A; Azizi M; Plouin PF
Eur J Endocrinol; 2015 Mar; 172(3):R125-9. PubMed ID: 25315875
[TBL] [Abstract][Full Text] [Related]
13. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
[TBL] [Abstract][Full Text] [Related]
14. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
Kline GA; Pasieka JL; Harvey A; So B; Dias VC
Ann Surg Oncol; 2013 Jul; 20(7):2274-8. PubMed ID: 23504117
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
[TBL] [Abstract][Full Text] [Related]
17. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
18. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
[TBL] [Abstract][Full Text] [Related]
19. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
Morimoto S; Ichihara A
Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
[TBL] [Abstract][Full Text] [Related]
20. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
